Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis
暂无分享,去创建一个
[1] Zhen-Zhen Sun,et al. Hepcidin expression in patients with acute leukaemia , 2012, European journal of clinical investigation.
[2] Herbert Y. Lin,et al. Targeting the hepcidin–ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation , 2012, American journal of hematology.
[3] A. Tefferi,et al. One thousand patients with primary myelofibrosis: the mayo clinic experience. , 2012, Mayo Clinic proceedings.
[4] M. Muckenthaler,et al. Second Round Robin for plasma hepcidin methods : First steps toward harmonization , 2012 .
[5] M. Cazzola,et al. Iron overload and iron chelation therapy in patients with myelodysplastic syndrome treated by allogeneic stem‐cell transplantation: Report from the working conference on iron chelation of the Gruppo Italiano Trapianto di Midollo Osseo , 2011, American journal of hematology.
[6] Tomas Ganz,et al. Hepcidin and iron regulation, 10 years later. , 2011, Blood.
[7] A. Tefferi,et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] F. Passamonti,et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] D. Girelli,et al. Hepcidin Levels and Their Determinants in Different Types of Myelodysplastic Syndromes , 2010, PloS one.
[10] A. Tefferi,et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients , 2010, Leukemia.
[11] Pan-pan Cheng,et al. Hepcidin expression in anemia of chronic disease and concomitant iron-deficiency anemia , 2011, Clinical and Experimental Medicine.
[12] Ayalew Tefferi,et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.
[13] Matthias W. Hentze,et al. Two to Tango: Regulation of Mammalian Iron Metabolism , 2010, Cell.
[14] Dominica H. C. Wong,et al. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy , 2009, Hematological oncology.
[15] V. Pullarkat. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? , 2009, Blood.
[16] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[17] T. Ganz,et al. Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis , 2008, British journal of haematology.
[18] S. Goh,et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin , 2007, Nature Medicine.
[19] A. Tefferi,et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia , 2007, Cancer.
[20] T. Ganz,et al. Liver iron concentrations and urinary hepcidin in beta-thalassemia. , 2007, Haematologica.
[21] Jerry Kaplan,et al. Hepcidin Regulates Cellular Iron Efflux by Binding to Ferroportin and Inducing Its Internalization , 2004, Science.